Brazil's National Health Surveillance Agency (Anvisa) has updated the List of Qualified Impurities in Medicines, a fundamental technical document for the national pharmaceutical industry and product regulation.
The update reflects the agency's commitment to maintaining high standards of quality and safety in pharmaceutical manufacturing. The list specifies acceptable limits for impurities that may be present in pharmaceutical formulations, considering scientific and international criteria.
Qualified impurities are unwanted substances that may arise during the synthesis, manufacture, or storage of a medicine. Their control is essential to ensure that commercially available products meet quality requirements established by regulatory authorities.
Anvisa's list update is the result of continuous technical analysis of safety, efficacy, and quality data available in the global market. This type of document provides clear guidance to manufacturers regarding which impurities are acceptable and at what concentrations, facilitating compliance with current regulations.
The initiative is aligned with international good manufacturing practices (GMP) and guidelines from reference regulatory agencies worldwide, such as the FDA and EMA.
For the pharmaceutical industry, the update represents an opportunity to align production processes with the most recent standards, ensuring regulatory compliance. Manufacturers and importers of medicines should consult the updated list to adapt their quality control protocols.
Anvisa makes these technical documents available for public consultation, contributing to regulatory transparency and strengthening the Brazilian pharmaceutical market.
